Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Paul Hudson

- PMLiVE

AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

- PMLiVE

Sanofi gains rights to Fulcrum’s muscular dystrophy treatment in deal worth more than $1bn

Losmapimod is being investigated as a potential transformative therapy for the rare disease

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

- PMLiVE

Sanofi and Novavax announce COVID-19 vaccine licensing agreement worth over $1.2bn

The deal gives Sanofi a licence to use Novavax’s COVID-19 vaccine in combination with its own flu vaccines

- PMLiVE

AstraZeneca/Sanofi reveal promising real-world data for Beyfortus in infant RSV

The treatment reduced RSV hospitalisations by 82% in infants under six months during the 2023 to 2024 RSV season

- PMLiVE

Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A

The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

Biogen Idec building

Biogen’s tocilizumab biosimilar Tofidence recommended by CHMP to treat arthritis and COVID-19

The committee’s decision was supported by evidence demonstrating Tofidence’s similarity to Roche’s RoActemra

- PMLiVE

Sanofi presents positive phase 3 results for rilzabrutinib in immune thrombocytopenia

The late-stage LUNA 3 study results will be presented at a medical congress later this year

- PMLiVE

Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

Sanofi announces UK launch of inactivated rabies vaccine Verorab for all age groups

The rare neurotrophic virus is responsible for an estimated 59,000 global deaths every year

- PMLiVE

Co-funded trial shows promise for Sanofi’s diabetes drug in early Parkinson’s disease

According to WHO, the neurodegenerative disease affected more than 8.5 million people worldwide in 2019

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links